Previous Close | 22.40 |
Open | 22.92 |
Bid | 23.06 x 800 |
Ask | 24.57 x 800 |
Day's Range | 21.02 - 23.38 |
52 Week Range | 20.49 - 97.43 |
Volume | |
Avg. Volume | 1,425,467 |
Market Cap | 2.206B |
Beta (5Y Monthly) | 1.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.12 |
Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 86.26 |
Fate Therapeutics, Inc. ( NASDAQ:FATE ) shareholders might understandably be very concerned that the share price has...
SAN DIEGO, May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences: BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022 at 12:20 PM ET in Las Vegas, NevadaH.C. Wainwright Annual Global Life Science
FATE reports a narrower loss and higher collaboration revenues in the first quarter.